JP2013528640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528640A5 JP2013528640A5 JP2013514789A JP2013514789A JP2013528640A5 JP 2013528640 A5 JP2013528640 A5 JP 2013528640A5 JP 2013514789 A JP2013514789 A JP 2013514789A JP 2013514789 A JP2013514789 A JP 2013514789A JP 2013528640 A5 JP2013528640 A5 JP 2013528640A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- oxo
- urea
- tert
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 15
- -1 C 6 aryl Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- GRFBNEAPKLWFPA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[(1-methyl-2-oxo-3h-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N(C)C(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 GRFBNEAPKLWFPA-UHFFFAOYSA-N 0.000 claims 2
- CWIGGHRHBFIADD-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[(2-oxo-1,3-dihydroimidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4NC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 CWIGGHRHBFIADD-UHFFFAOYSA-N 0.000 claims 2
- QGFOJZMDPXDGSA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[8-[(2-oxo-1,3-dihydroimidazo[4,5-b]pyridin-7-yl)oxy]quinolin-5-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CN=C3C(OC=3C=4NC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 QGFOJZMDPXDGSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- FPSYUXXLCHMFRU-UHFFFAOYSA-N 1-[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound N1=C(C(C)C)C=C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)N1C1=CC=C(C)C=C1 FPSYUXXLCHMFRU-UHFFFAOYSA-N 0.000 claims 1
- KADWMAJVBHJWDX-UHFFFAOYSA-N 1-[5-cyclopropyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)=CC(C2CC2)=N1 KADWMAJVBHJWDX-UHFFFAOYSA-N 0.000 claims 1
- SSIFHFIRVJXKOP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(3,4-dichlorophenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)N1C1=CC=C(Cl)C(Cl)=C1 SSIFHFIRVJXKOP-UHFFFAOYSA-N 0.000 claims 1
- DAXMIVDYBBFSGN-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-chlorophenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)N1C1=CC=C(Cl)C=C1 DAXMIVDYBBFSGN-UHFFFAOYSA-N 0.000 claims 1
- YEXAEGWRSZOFGW-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-hydroxyphenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)N1C1=CC=C(O)C=C1 YEXAEGWRSZOFGW-UHFFFAOYSA-N 0.000 claims 1
- UUDAKQZBMTXFJA-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[2,3-dichloro-4-[(1-methyl-2-oxo-3h-imidazo[4,5-b]pyridin-7-yl)oxy]phenyl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C(=C(Cl)C(OC=3C=4N(C)C(=O)NC=4N=CC=3)=CC=2)Cl)=CC(C(C)(C)C)=N1 UUDAKQZBMTXFJA-UHFFFAOYSA-N 0.000 claims 1
- HYEOMJSVLMONGY-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[(1-ethyl-2-oxo-3h-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CN=C2NC(=O)N(CC)C2=C1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(OC)C=C1 HYEOMJSVLMONGY-UHFFFAOYSA-N 0.000 claims 1
- URQAXVPGUSETSW-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[(2-oxo-1-propan-2-yl-3h-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N(C(C)C)C(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 URQAXVPGUSETSW-UHFFFAOYSA-N 0.000 claims 1
- IBHXVVYFEIGWLJ-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 IBHXVVYFEIGWLJ-UHFFFAOYSA-N 0.000 claims 1
- BBDYTNGLQLQTOV-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylsulfanylphenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(SC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 BBDYTNGLQLQTOV-UHFFFAOYSA-N 0.000 claims 1
- PDQILYUWWBSUJV-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylsulfonylphenyl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)N1C1=CC=C(S(C)(=O)=O)C=C1 PDQILYUWWBSUJV-UHFFFAOYSA-N 0.000 claims 1
- KIPZYDCBLYBUMY-UHFFFAOYSA-N 1-[5-tert-butyl-2-(5-methylthiophen-2-yl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound S1C(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 KIPZYDCBLYBUMY-UHFFFAOYSA-N 0.000 claims 1
- QAKIGHBHPHZCJC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]-3-[4-[(1-methyl-2-oxo-3h-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=NC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N(C)C(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 QAKIGHBHPHZCJC-UHFFFAOYSA-N 0.000 claims 1
- LZBHCIKYEDQJHN-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=NC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 LZBHCIKYEDQJHN-UHFFFAOYSA-N 0.000 claims 1
- WHKSAKSSQHTIKP-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(hydroxymethyl)phenyl]pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound N1=C(C(C)(C)C)C=C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)N1C1=CC=C(CO)C=C1 WHKSAKSSQHTIKP-UHFFFAOYSA-N 0.000 claims 1
- FJCORFQIRVXPCY-UHFFFAOYSA-N 1-[5-tert-butyl-2-[4-(methylsulfamoylmethyl)phenyl]pyrazol-3-yl]-3-[4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CC(CS(=O)(=O)NC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=4N=CC(=O)NC=4N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 FJCORFQIRVXPCY-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- XNQSTULIVOPNQM-UHFFFAOYSA-N C12=CC=CC=C2C(NC(=O)N)=CC=C1OC1=CC=NC2=C1N=CC(=O)N2 Chemical compound C12=CC=CC=C2C(NC(=O)N)=CC=C1OC1=CC=NC2=C1N=CC(=O)N2 XNQSTULIVOPNQM-UHFFFAOYSA-N 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000002664 inhalation therapy Methods 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1010190.5 | 2010-06-17 | ||
| GBGB1010190.5A GB201010190D0 (en) | 2010-06-17 | 2010-06-17 | Novel compounds |
| GBGB1101640.9A GB201101640D0 (en) | 2011-01-31 | 2011-01-31 | Novel compounds |
| GB1101640.9 | 2011-01-31 | ||
| PCT/GB2011/051141 WO2011158044A2 (en) | 2010-06-17 | 2011-06-17 | Respiratory formulations and compounds for use therein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528640A JP2013528640A (ja) | 2013-07-11 |
| JP2013528640A5 true JP2013528640A5 (cg-RX-API-DMAC7.html) | 2014-07-24 |
| JP5973426B2 JP5973426B2 (ja) | 2016-08-23 |
Family
ID=44514329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514789A Active JP5973426B2 (ja) | 2010-06-17 | 2011-06-17 | Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8933228B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2582700B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5973426B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011158044A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2709257C (en) | 2007-12-19 | 2016-12-13 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| ES2469367T3 (es) | 2010-02-01 | 2014-06-18 | Cancer Research Technology Limited | 1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| JP5973426B2 (ja) | 2010-06-17 | 2016-08-23 | レスピバート・リミテツド | Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| CA2846222C (en) | 2011-10-03 | 2020-07-07 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1- yl) ureas as p38 map kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| KR102283883B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| US9890185B2 (en) | 2013-12-20 | 2018-02-13 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| CA2938924C (en) | 2014-02-14 | 2023-01-31 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| CN109071505B (zh) | 2016-04-06 | 2021-11-16 | 奥苏拉收购有限公司 | 激酶抑制剂 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR20220038696A (ko) * | 2019-07-19 | 2022-03-29 | 아나제네시스 바이오테크놀로지스 에스.에이.에스. | 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| SI1165516T1 (sl) | 1999-03-12 | 2005-02-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterociklična sečnina in sorodne spojine, uporabne kot protivnetna sredstva |
| CA2576297C (en) | 2004-08-12 | 2011-01-25 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| AR056582A1 (es) | 2005-10-28 | 2007-10-10 | Lilly Co Eli | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE |
| AR065858A1 (es) | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona. |
| CN101636397B (zh) | 2007-04-13 | 2012-06-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 脲类化合物、其制备方法及其医药用途 |
| CA2709257C (en) | 2007-12-19 | 2016-12-13 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| NZ587907A (en) | 2008-03-17 | 2012-09-28 | Ambit Biosciences Corp | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| MX2011003553A (es) * | 2008-10-02 | 2011-05-25 | Respivert Ltd | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38. |
| GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| JP2012511563A (ja) | 2008-12-11 | 2012-05-24 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| WO2010106713A1 (ja) | 2009-03-18 | 2010-09-23 | シャープ株式会社 | 液晶表示装置およびその駆動方法 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| WO2011124930A1 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | P38 map kinase inhibitors |
| EP2556067B1 (en) | 2010-04-08 | 2016-02-24 | Respivert Limited | Pyrazolyl ureas as p38 map kinase inhibitors |
| JP5973426B2 (ja) | 2010-06-17 | 2016-08-23 | レスピバート・リミテツド | Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤 |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
-
2011
- 2011-06-17 JP JP2013514789A patent/JP5973426B2/ja active Active
- 2011-06-17 EP EP11729151.8A patent/EP2582700B1/en active Active
- 2011-06-17 WO PCT/GB2011/051141 patent/WO2011158044A2/en not_active Ceased
- 2011-06-17 US US13/805,471 patent/US8933228B2/en active Active
-
2014
- 2014-12-05 US US15/530,681 patent/US10358445B2/en active Active